Encarnacao R. Teixeira

Lisbon, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Addressing Challenges to Enhance Clinical Research in Portugal: Insights from the OncoT3 Expert Group Delphi Study.

Addressing Challenges to Enhance Clinical Research in Portugal: Insights from the OncoT3 Expert Group Delphi Study.

Journal: Cureus

Published: November 11, 2024

Cost-effectiveness of lung cancer screening with volume computed tomography in Portugal.

Cost-effectiveness of lung cancer screening with volume computed tomography in Portugal.

Journal: Journal of comparative effectiveness research

Published: September 27, 2024

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 10, 2024

Management of infusion-related reactions in cancer therapy: strategies and challenges.

Management of infusion-related reactions in cancer therapy: strategies and challenges.

Journal: ESMO open

Published: November 14, 2023

Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.

Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.

Journal: Acta medica portuguesa

Published: December 10, 2021

Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel.

Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel.

Journal: Pulmonology

Published: November 08, 2021

Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR.

Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR.

Journal: Translational lung cancer research

Published: April 23, 2021

T790M-EGFR mutation frequency in advanced NSCLC patients on progression from a previous TKI therapy: results from a Portuguese study.

T790M-EGFR mutation frequency in advanced NSCLC patients on progression from a previous TKI therapy: results from a Portuguese study.

Journal: Pulmonology

Published: November 11, 2020

Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study.

Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study.

Journal: Pulmonology

Published: November 06, 2019

Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.

Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 06, 2019

Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).

Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).

Journal: Pulmonology

Published: February 26, 2019

Characterization and management of elderly and very elderly patients with non-small cell lung cancer.

Characterization and management of elderly and very elderly patients with non-small cell lung cancer.

Journal: The clinical respiratory journal

Published: January 04, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026